• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: CODMAN AND SHURTLEFF, INC STENT - VASCULAR RECONSTRUCTION; INTRACRANIAL NEUROVASCULAR STENT

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

CODMAN AND SHURTLEFF, INC STENT - VASCULAR RECONSTRUCTION; INTRACRANIAL NEUROVASCULAR STENT Back to Search Results
Catalog Number UNK-CNV ENTERPRISE SES
Device Problem Adverse Event Without Identified Device or Use Problem (2993)
Patient Problems Stroke/CVA (1770); Death (1802)
Event Date 02/28/2018
Event Type  Injury  
Manufacturer Narrative
Product complaint # (b)(4).Since the product was not returned for analysis, no product failure analysis can be conducted and no determination of possible contributing factors could be made.Device history record (dhr) review cannot be conducted because no lot number was provided by the customer.Missing information from this report is identified as blank; this information was not provided in the reported event or available at the time of report submission.Information regarding patient weight, height, medical history, race, and ethnicity was not reported.Cerenovus manufacturer's report numbers: 1226348-2020-00038, 1226348-2020-00039, 1226348-2020-00040, 1226348-2020-00041 are related to the same incident.
 
Event Description
This complaint is from a literature source.As reported in the literature publication entitled, ¿stent angioplasty for acute intracranial atherosclerotic occlusion after failed thrombectomy: a single-institution series of 55 patients¿.4 patients with acute stroke and intracranial atherosclerotic occlusion who underwent endovascular artery thrombectomy and the following endovascular stent implantation died for 90 days after operation objective: analysis of safety and effectiveness of stent angioplasty for the failure of thrombectomy in patients with acute intracranial atherosclerotic occlusion.Methods: retrospective continuous analysis of the clinical data of 458 patients with acute stroke undergoing endovascular artery thrombectomy from may 2013 to february 2018.Patients with acute intracranial atherosclerotic occlusion treating with stent implantation were included and the safety and effectiveness of stent angioplasty was evaluated.
 
Manufacturer Narrative
Sample was received for evaluation: dhr - product code 82-3113 with lot crcc07; sn (b)(6), conformed to the specifications when released to stock on the 31st march 2014.Gtin (b)(4).Failure analysis - the valve was visually inspected; the stator was dislodged as well as a bump marks in the valve casing were noted.The valve could not be program or pressure tested due to the dislodged stator.The valve was dismantled and was examined under microscope at appropriate magnification: bump marks were noted in the valve casing; corrosion was also noted on the stator.The cam magnets passed per internal process.The root cause for the dislodged stator and bump mark in the valve casing is due to the valve receiving a hard knock.The root cause of the corrosion could not be clearly determined.Between 05nov2019 and 30jun2020, approximately 2,200 mdrs submitted electronically by integra lifesciences via trackwise, integra's complaint handling system, were not received by cdrh due to a computer system issue.Within this time period, an error with integra's middleware, which facilitates communications between trackwise and the fda system, caused the complaint records to close and indicate we had received an acknowledgement 3 from the fda when we had not.Integra interpreted the acknowledgement as a successful submission; however, subsequent investigation revealed the acknowledgement 3 received was from our middleware and not from the fda (these acknowledgements have been retained as part of the documentation of the mdr).The malfunction was related to the relocation of the trackwise application to a new data center during the transition of integra's corporate headquarters from plainsboro, nj to princeton, nj.Previously, integra had been successfully receiving acknowledgements 1, 2, and 3 from the fda, and our records reflect these acknowledgements, including the date and time stamps.Capa pr 229048 and nc 20-011 have been opened by integra to further investigate the nonconformance and develop a corrective action plan.The middleware error has been corrected, and integra has filed mdrs since the correction and verified that the appropriate acknowledgements have been received from the fda.Integra is resubmitting all impacted mdr reports for the time period 05nov2019 through 30jun2020.Integra lifesciences contacted (b)(6), director of regulatory programs, office of product evaluation and quality and (b)(6), assistant director, mdr team, office of product evaluation and quality on july 8-9, 2020 to report these issues regarding mdr reports.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
STENT - VASCULAR RECONSTRUCTION
Type of Device
INTRACRANIAL NEUROVASCULAR STENT
Manufacturer (Section D)
CODMAN AND SHURTLEFF, INC
325 paramount dr
raynham MA 02767
MDR Report Key10010469
MDR Text Key189357908
Report Number1226348-2020-00042
Device Sequence Number1
Product Code NJE
Combination Product (y/n)N
PMA/PMN Number
UNK
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type foreign,literature
Type of Report Initial,Followup
Report Date 04/08/2020
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received04/29/2020
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Health Professional
Device Catalogue NumberUNK-CNV ENTERPRISE SES
Was Device Available for Evaluation? Device Returned to Manufacturer
Date Returned to Manufacturer02/18/2020
Date Manufacturer Received03/17/2020
Is This a Reprocessed and Reused Single-Use Device? No
Patient Sequence Number1
Patient Outcome(s) Death;
Patient Age65 YR
-
-